Bio-Path Holdings(BPTH)
BELLAIRE, TX
BiotechnologyFocus: Antisense DNA therapeutics
Bio-Path Holdings is a life sciences company focused on Antisense DNA therapeutics.
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
L-Bcl-2 antisense oligonucleotide
Mantle Cell LymphomaClinical Trials (1)
NCT04072458A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Phase 1BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Acute Myeloid Leukemia, in RelapseClinical Trials (1)
NCT05190471A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Phase 1Phase 1
Clinical Trials (1)
NCT01159028Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Phase 1BP1001-A
Solid Tumor, AdultClinical Trials (1)
NCT04196257BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1Phase 1/2
Clinical Trials (1)
NCT02923986Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Phase 1/2BP1001 in combination with Ventoclax plus decitabine
Acute Myeloid Leukemia (AML)Clinical Trials (1)
NCT02781883Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 6 clinical trials
SEC Filings: 2 available